
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is well-positioned for growth due to its innovative approach in addressing treatment-resistant depression (TRD) through its proprietary COMP360 psilocybin therapy, which exhibits superior efficacy compared to existing treatments like Spravato, which has surpassed $1 billion in annual revenue. The company’s phase 2b data suggest that maintaining similar efficacy while optimizing dosing frequency could enhance COMP360's market appeal and commercial potential, supported by a favorable safety profile. With the broader momentum in the psychedelics market, there is a promising outlook for COMP360, particularly given its demonstrated rapid reductions in depressive and anxious symptoms, indicating a strong demand for effective mental health therapies.
Bears say
Compass Pathways's stock outlook is negatively impacted by several fundamental concerns regarding its clinical development and regulatory environment. The uncertainty surrounding the efficacy of its lead product, COMP360, especially given the context of Lykos Therapeutics' negative AdComm and subsequent CRL, raises questions about the company's ability to achieve clinically meaningful benefits in its phase III trials. Additionally, the heightened scrutiny from the FDA and potential failure to commercialize may result in significant downside risks to earnings estimates, which could lead to considerable stock price volatility for Compass Pathways.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares